SCHEMBL18924751

SCHEMBL18924751

CC/C=C\CCCC(=O)OCC

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.89
NR1I2 O75469 2/20 0.89
PTGS2 P35354 2/20 0.89
PGR P06401 1/20 0.89
PDE4D Q08499 1/20 0.89
ALDH1A1 P00352 6/20 0.77
CYP3A4 P08684 2/20 0.77
ALOX15 P16050 2/20 0.77
HSD17B10 Q99714 2/20 0.77
TDP1 Q9NUW8 2/20 0.77
TSHR P16473 1/20 0.77
CYP1A2 P05177 1/20 0.59
F7 P08709 3/20 0.53
CYP19A1 P11511 3/20 0.53
F3 P13726 3/20 0.53
PTGS1 P23219 2/20 0.53
PPARG P37231 2/20 0.53
KMT2A Q03164 2/20 0.53
PPARD Q03181 2/20 0.53
PPARA Q07869 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Icosapent Ethyl SCHEMBL28253974 0.94 ADORA3 (1.00) ADORA3NR1I2PTGS2PGRPDE4D
Icosapent Ethyl SCHEMBL119167 0.94 ADORA3 (1.00) ADORA3NR1I2PTGS2PGRPDE4D
Icosapent Ethyl SCHEMBL123305 0.94 ADORA3 (1.00) ADORA3NR1I2PTGS2PGRPDE4D
Icosapent Ethyl SCHEMBL28366934 0.94 ADORA3 (1.00) ADORA3NR1I2PTGS2PGRPDE4D
Icosapent Ethyl SCHEMBL119168 0.94 ADORA3 (1.00) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL28420707 0.94 ALDH1A1 (0.87) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL11330132 0.94 NR1I2 (0.79) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL11330152 0.94 NR1I2 (0.79) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL12614123 0.92 ALDH1A1 (0.90) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL31512534 0.92 ALDH1A1 (0.90) ADORA3NR1I2PTGS2PGRPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 US disclosed
US-12427176-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2025-09-30 US disclosed
US-12303488-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-05-20 US disclosed
EP-4417252-A2 CANNABIS BASED THERAPEUTIC AND METHOD OF USE Yuzu LV LLC (US) 2024-08-21 EP disclosed
US-20240216457-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 US disclosed
US-20240216456-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-07-04 US disclosed
US-20240207342-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-06-27 US disclosed
US-20240207344-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2024-06-27 US disclosed
US-11883454-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2024-01-30 US disclosed
US-20230405067-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2023-12-21 US disclosed
CN-114831141-B New use of Glycyrrhrizae radix and alhagi sparsifolia volatile compounds 新疆农业科学院植物保护研究所 2023-11-03 CN disclosed
US-20230346739-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-11-02 US disclosed
US-20230293555-A1 COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES YUZU LV LLC 2023-09-21 US disclosed
US-20230293480-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC 2023-09-21 US disclosed
US-11684604-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2023-06-27 US disclosed
US-20220387537-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2022-12-08 US disclosed
CN-114831141-A New application of volatile compounds of liquorice and alhagi sparsifolia 新疆农业科学院植物保护研究所 2022-08-02 CN disclosed
US-9670200-B2 Quaternary ammonium salt prodrugs ALKERMES PHARMA IRELAND LIMITED (IE) 2017-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684604-B2 Cannabis based therapeutic and method of use CNR2, CNR1, OPRK1 ADORA3 1107/4885NR1I2 1707/4885PTGS2 733/4885
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 ADORA3 1932/4885NR1I2 461/4885PTGS2 329/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 ADORA3 3889/4885NR1I2 2724/4885PTGS2 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.